Superior Efficacy of a TBI-166, Bedaquiline, and Pyrazinamide Combination Regimen in a Murine Model of Tuberculosis-Reference-Cited by-同舟云学术

Superior Efficacy of a TBI-166, Bedaquiline, and Pyrazinamide Combination Regimen in a Murine Model of Tuberculosis

Published:2022-09-20 Issue:9 Volume:66 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Ding Yangming¹,Zhu Hui¹,Fu Lei¹,Zhang Weiyan¹,Wang Bin¹,Guo Shaochen¹,Chen Xi¹,Wang Ning¹,Liu Haiting¹,Lu Yu¹^ORCID

Affiliation:

1. Beijing Key Laboratory of Drug Resistance Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China

Abstract

TBI-166, derived from riminophenazine analogues, shows more potent anti-TB activity than clofazimine and is being assessed against tuberculosis (TB) in a phase IIa clinical trial in China. Preclinical regimen studies containing TBI-166 will support the phase IIb clinical trials of TBI-166.

Funder

National Natural Science Foundation of China

Beijing Hospital Authority

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.00658-22

Reference21 articles.

1. World Health Organization. 2021. Global tuberculosis report. World Health Organization, Geneva, Switzerland.

2. Clofazimine Analogs with Efficacy against Experimental Tuberculosis and Reduced Potential for Accumulation